FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
Saved in:
| Title: | FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. |
|---|---|
| Authors: | Brodowicz, T.1,2, Ciuleanu, T. E.3, Radosavljevic, D.4, Shacham-Shmueli, E.5, Vrbanec, D.6, Plate, S.7, Mrsic-Krmpotic, Z.8, Dank, M.9, Purkalne, G.10, Messinger, D.11, Zielinski, C. C.1,2 |
| Source: | Annals of Oncology. Jul2013, Vol. 24 Issue 7, p1769-1777. 9p. 1 Diagram, 4 Charts, 1 Graph. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
